GW Pharmaceuticals received some good news from the FDA a few days ago as they approved the use of Epidiolex “for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older.” Previously, Epidiolex had the FDA’s approval to treat seizures from two rare forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS).
Currently, GW Pharmaceuticals is the leading assignee of patents related to cannabis, especially for the use of cannabinoids in the treatment of epilepsy and other neurological disorders. GW’s portfolio nearly spans the entire Magic Number Cannabis Patent Forecast®.
Explore GW Pharmaceuticals’ extensive cannabis patent portfolio at an advantage using Magic Number’s Cannabis Patent Forecast®.
